Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Veligrotug demonstrated significant improvements in proptosis, diplopia, and clinical activity score among patients with active thyroid eye disease.

Diazoxide choline extended-release tablets demonstrated favorable safety profile across 4 years among patients with Prader-Willi Syndrome.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.